ClinicalTrials.gg

Program

CD19 t-haNK- IV Administration

Its studies are mostly in Lymphoma, B-Cell, led by ImmunityBio.

Furthest: phase 2, since Aug 11, 20251 company-led study, 1 open or runningNext primary completion: May 25, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ImmunityBio11 open or runningphase 2since Aug 11, 2025Aug 11, 2025May 25, 2027phase 2 · NCT07125872

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2025First study: phase 2 study in Lymphoma, B-CellFirst studyNCT07125872 · 20 planned · South Africa

Ahead

  1. May 25, 2027Primary completion: phase 2 study in Lymphoma, B-CellNCT07125872

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07125872Lymphoma, B-Cell · South Africa2RecruitingMay 25, 202720

How it is read

Names in the registry

  • “CD19 t-haNK- IV Administration”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.